...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
【24h】

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

机译：Inotuzumab ozogamicin与低强度化疗（mini-hcvd）组合，有或没有Blinatumomab与标准密集化疗（HCVAD）作为老年人染色体阴性急性急性淋巴细胞白血病的前线治疗：倾向评分分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The outcome of older patients with newly diagnosed, Philadelphia chromosome (Ph)‐negative acute lymphoblastic leukemia (ALL) is poor. The combination of targeted therapy with low‐intensity chemotherapy is safe and effective. The objective of the current analysis was to compare the outcome of patients who received a combination of inotuzumab ozogamicin plus low‐intensity chemotherapy (mini–hyperfractionated cyclophosphamide, vincristine, and dexamethasone [mini‐HCVD]) with or without blinatumomab versus the outcome of those who received the standard, intensive, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) regimen. Methods The authors analyzed 135 older patients with newly diagnosed, Ph‐negative ALL who were treated prospectively with standard HCVAD (n?=?77) or with the combination of inotuzumab ozogamicin plus mini‐HCVD with or without blinatumomab (n?=?58). A propensity score analysis was conducted using 1:1 matching using the nearest neighbor matching method. Results Propensity score matching identified 38 patients in each cohort. The antibody plus low‐intensity chemotherapy combination induced higher response rates (98% vs 88%), with lower rates of early death (0% vs 8%) and lower rates of death in complete remission (5% vs 17%). With propensity score matching, the 3‐year event‐free survival rates for patients who received HCVAD and those who received the combination of inotuzumab ozogamicin plus mini‐HCVD with or without blinatumomab were 34% and 64%, respectively ( P ?=?.003), and the 3‐year overall survival rates were 34% and 63%, respectively ( P ?=?.004). By multivariate analysis, age ( P ?=?.019; hazard ratio, 1.045) and the combination of inotuzumab plus mini‐HCVD with or without blinatumomab ( P ?=?.020; hazard ratio, 0.550) were identified as independent prognostic factors for survival. Conclusions The combination of inotuzumab ozogamicin plus mini‐HCVD with or without blinatumomab is safe and effective in older patients with newly diagnosed, Ph‐negative ALL and confers a better outcome compared with standard HCVAD chemotherapy.
机译：背景技术老年患者的新诊断患者的结果，费城染色体（pH） - 负急性淋巴细胞白血病（全部）是穷人。具有低强度化疗的靶向治疗的组合是安全可有效的。目前的分析的目的是比较接受Inotuzumab ozogamicin加低强度化疗（迷你过度分布环磷酰胺，长氨基和地塞米松和地塞米松[Mini-HCVD]的患者的结果，或没有Blinatumomab与那些结果相比谁收到标准，密集型，高度分布的环磷酰胺，长春新碱，多柔比星和地塞米松（HCVAD）方案。方法采用作者分析了135名年龄较新诊断的患者，pH-Digal全部与标准HCVAD（n？=α77）进行治疗，或者在inotuzumab ozogamicin plus mini-hcvd的组合有或没有blinatumomab（n？=？58 ）。使用最近的邻居匹配方法使用1：1匹配来进行倾向分数分析。结果倾向得分匹配鉴定了每组队列中的38名患者。抗体加低强度化疗组合诱导较高的响应率（98％vs 88％），早死亡率较低（0％vs 8％），完全缓解的较低死亡率（5％vs 17％）。具有倾向得分匹配，接受HCVAD的患者的3年无需存活率和接受inotuzumab ozogamicin加上迷你-hcvd的组合分别为34％和64％（P？= ?. 003），3年的总生存率分别为34％和63％（P？= 004）。通过多变量分析，年龄（p？= 019;危害比，1.045）和inotuzumab加上迷你-hcvd的组合，有或没有blinatumomab（p？= 020;危害比，0.550）被鉴定为独立的预后因素为了生存。结论在新诊断的新诊断，pH阴性所有患者中，inotuzumab ozogamicin加迷你-hcvd的组合是安全有效的，与标准HCVAD化疗相比更好的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号